The Special Case of Gene Therapy Pricing

Nat Biotechnol. 2014 Sep;32(9):874-6. doi: 10.1038/nbt.3003.

Abstract

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.

MeSH terms

  • Genetic Therapy / economics*
  • Humans
  • Reimbursement Mechanisms